Saniona Seeks Partners To Secure Survival
Tough Year For Danish Biotech
CEO Thomas Feldthus's new broom is sweeping clean at Saniona with the closure of its US operations and an aim of exploiting the significant interest being shown across its pipeline programs.
You may also be interested in...
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.